The pathologic and baseline clinical characteristics (histologic subtype, PD-L1 or tumor mutational burden (TMB) status; occurrence of treatment-related adverse events (TRAEs); pathologic evidence of LN involvement) are shown in Fig. 2 and Supplementary Table 2, and no clear patterns of association were observed between depth of pathologic response and these features, though some subgroups were small. Here, CD274 is linked to neoplasm.